Grow your brand, now and through patent expiry


Glucagon-like-peptide-1 agonists ("GLP-1s") are an important growth driver for the biopharmaceutical industry both in terms of sales and demand. They have made headlines over the past several months as shortages, compounding, telehealth partnerships, and policy impact the diabetes and weight loss markets. In a recent webinar, IQVIA shared insights on the latest trends, the role of pharmacy compounding and telehealth, and key considerations for the next three to five years. This information is summarized for you in the Insights Brief - How Patients Are Accessing GLP-1s Through Alternative Channels.
Download now for more detail.
Grow your brand, now and through patent expiry
We empower life sciences with connected intelligence, transforming data into actionable insights for smarter decisions and better patient outcomes.